Middle East respiratory syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2
virus

Middle East respiratory syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2

EVAg
Produced by
: IP
Shipping From
: Paris - FR

Product Description

Ref-SKU:
014V-02970
Middle East respiratory syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2
Product Risk Group: 
RG3
ICTV Taxonomy: 
Riboviria / Orthornavirae / Pisuviricota / Pisoniviricetes / Nidovirales / Cornidovirineae / Coronaviridae / Orthocoronavirinae / Betacoronavirus / Merbecovirus / Middle East respiratory syndrome-related coronavirus
Virus name: 
MERS-CoV
Strain: 
IP/COV/MERS/Hu/France/FRA2
Isolate: 
Human, sputum

Storage conditions: 
Viral Storage Medium -80C
Sequencing: 
Complete genome
Infectivity: 
Infectivity tested and quantified
Mycoplasmic content: 
Mycoplasma free

Unit definition: 
1 vial (500 µL)

In stock

1 000,00 €
 (Cost per access for Academics)
Free access available

catalogue

biobank

Portal

EVAg

purchase

buy

order

price

cost

shipping

shipment

experiment

research

laboratory

viral

virus

GMO: 
No
Virus host type: 
Human virus
Infectivity Test: 
TCID50
Viral titer: 
4.63 log10 TCID50/mL
Production cell line: 
Vero E6
Genbank reference: 
KJ361503
Virus Cultivability: 
Cultivable virus
Passage: 
C3
Identification technique: 
qRT-PCR, HTS
Shipping conditions: 
Dry ice
IATA Classification: 
Category A, UN2814
Note: 

Supernatant free from VeroE6 cells or debris.

Information about the collection of the virus

Recombinant product: 
No
Biological material origin: 
Natural origin
Collection date: 
Monday, 13 May, 2013
Country of collection: 
France
Suspected epidemiological origin : 
France
Isolation host: 
Human

Comments (1)

  • b.martina's picture

    Dear Sir Madam,

    I would like to request a quotation for the Middle East Respiratory Syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2 with Ref-SKU: 014V-02970. This pertains to a price estimate for setting up a series of diagnostic tests for a commercial entity.

    Kind regards,
    B. Martina.

    Apr 04, 2024